Nadav Kidron - 30 Mar 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: President and CEO, Director
Issuer ticker: ORMP
Reported as of: 30 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2026, 16:10:40 UTC
Prior SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Nadav Kidron

Key filing fact

Nadav Kidron filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 31 Mar 2026.

Key facts

This page summarizes Nadav Kidron's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Mar 2026, 16:10.

Change

Previous filing in this sequence was filed on 27 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001351779 Primary reporting owner

KIDRON NADAV

Relationship: President and CEO, Director
Address: 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK
Signature: /s/ Nadav Kidron
Signature date: 31 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Tax liability

Transaction value
Shares: -44,818
Change %: -1.3%
Price: $3.31^*
Shares after: 3,422,243
Date: 30 Mar 2026
Ownership: Direct
Footnotes: F1

ORMP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 126,000
Date: 30 Mar 2026
Ownership: By wholly-owned corporation

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock, par value $0.012 per share ("Common Stock"), of the Issuer used to satisfy tax withholding obligations attributable to the vesting and settlement of Restricted Stock Units, which were valued at the closing price of the Issuer's Common Stock on the date immediately prior to the vesting date, equal to $3.31 per share.